Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone

RIVERSIDE, Calif., Aug. 27, 2015 /PRNewswire/ -- ieCrowd™ today announced the achievement of an important milestone in the commercial development of the company's supplemental oxygen delivery device, Smart Oxygen^TM. The Smart Oxygen device, being developed by ieCrowd's subsidiary Smart Oxygen Solutions^TM, automatically adjusts to a patient's changing demand for oxygen based on level of activity.  The FDA agreed that the 510 (k) submission for the Smart Oxygen device would require a series of technical laboratory and bench performance tests, but that no further clinical study would be needed. This streamlined submission, as compared to a submission that includes clinical trials, confirms what Smart Oxygen Solutions believes will be its timeline for making the product commercially available. The Company anticipates having licensing agreements and being manufacture ready as early as 2016. The regulatory pathway was clarified during a technical review meeting, held in response to the company's "pre-submission" application for the device.

Smart Oxygen is designed for use by patients who need supplemental oxygen such as those with advanced COPD (Chronic Obstructive Pulmonary Disease). COPD is the 3^rd leading cause of death in the U.S. with an estimated 14.8 million diagnosed patients and another 12 million undiagnosed. COPD is the 2^nd leading cause of death in China.

The Smart Oxygen device is designed to automatically adjust the level of supplemental oxygen delivered to a patient on a breath-to-breath basis. The device uses a novel and patent-pending algorithm and conserving function in order to deliver a dose of oxygen in response to a patient respiratory pattern, thus enabling the device to be responsive to a patient's changing metabolic demand for oxygen, during daily activities such as walking, or any other type of exertion. By automating the dose of oxygen delivered based on a changing demand, it is expected that patients could maintain satisfactory blood oxygen levels without manually adjusting the oxygen flow rate. The result could be increased mobility and a more dynamic lifestyle for the patient that likely will benefit quality of life and exercise performance.

The underlying technology was licensed by Smart Oxygen Solutions from the University of California, San Diego, where the original version of the device was developed. Smart Oxygen Solutions has assembled a group of experts from UC San Diego on lung physiology, pulmonary medicine, and chronic advanced lung disease treatment to advise on the Smart Oxygen device.

"Pulmonary rehabilitation (PR) programs have been shown to improve exercise capacity, quality of life, and dyspnea in patients with pulmonary disorders, such as chronic obstructive pulmonary disease (COPD)," said Dr. Xavier Soler, MD, PhD, Associate Medical Director of the Pulmonary Rehabilitation Program at UC San Diego, Division of Pulmonary, Critical Care and Sleep medicine and Chief Medical Advisor to Smart Oxygen Solutions. "It is our hope that technologies like Smart Oxygen will advance the oxygen therapy field and help improve treatment in many pulmonary patients."

About Smart Oxygen Solutions, Inc.
Smart Oxygen Solutions, Inc.^TM (SOS), an ieCrowd company, is headquartered in Riverside, CA and is developing small, mobile oxygen delivery control devices designed to incorporate patient-adaptive dosing algorithms in a computer based system for use by people who need supplemental oxygen therapy. The largest categories of these patients are those with Chronic Obstructive Pulmonary Disease (COPD). The innovation was developed at the University of California, San Diego School of Engineering and licensed to Smart Oxygen Solutions. The technology has two international & U.S. patents pending.

About ieCrowd
Innovation Economy Corporation ("ieCrowd™") is an emerging growth company seeking to bring the world together to unlock the potential of untapped innovations. ieCrowd aligns itself with universities and research institutions to secure the rights to develop life, health and wellness innovations into what it believes may be transformative future products, platforms, services, and technologies. ieCrowd was founded in 2010 and is building a global ecosystem, based on a Collaborative Economy model, that includes investors, institutions, government agencies, universities, non-profits, companies, and individuals all committed to supporting ieCrowd's vision and mission. For more information about ieCrowd, visit www.iecrowd.com. Follow at @ieCrowd, https://linkedin.com/company/iecrowd and https://www.facebook.com/ieCrowd.

Forward-Looking Statements
Certain of the statements in this document may constitute forward-looking statements, including statements regarding future results of operations, financial condition, business strategy, operations, plans, prospects, revenue, costs and objectives. All forward-looking statements are subject to significant risks and uncertainties. There can be no assurance that any forward-looking statements will prove to be accurate, and the inclusion of any such statements should not be regarded as a representation or warranty that particular results, prospects or objectives will be achieved in any specified time frame, if at all. We undertake no obligation to update any forward-looking statements, except as required by law.

Media Contact: Larry Eason, [email protected], 951-374-0434

Logo - http://photos.prnewswire.com/prnh/20150604/220831LOGO

SOURCE Innovation Economy Corporation

Related Links

http://www.iecrowd.com